On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...